Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Behrens

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Rheumatology and Therapy|July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.
The Lancet. Rheumatology|January 30, 2024
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 studyLaura C Coates, William Tillett, Maria-Antonietta D'Agostino, et al.
RMD Open|December 19, 2023
Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trialMichaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Frontiers in Medicine|November 7, 2025
Effect of thyme-ivy syrup on antiviral immune response in patients with mild COVID-19: a prospective, open-label, randomized pilot studyStephanie Dauth, Stephan M G Schäfer, Maximilian Klippstein, et al.
Rheumatology and Therapy|March 18, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical TrialLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
Annals of the Rheumatic Diseases|March 30, 2007
Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritisFrank Behrens, Andrea Himsel, Stefan Rehart, et al.
Arthritis Care & Research|January 8, 2020
Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease ManifestationsPhilip J Mease, Dafna D Gladman, Alexis Ogdie, et al.
Annals of the Rheumatic Diseases|May 15, 2020
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trialClaudia Kedor, Joachim Listing, Jan Zernicke, et al.
Scientific Reports|January 14, 2025
Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infectionsSamuel Rischke, Robert Gurke, Ann-Sophie Zielbauer, et al.
Rheumatology (Oxford, England)|February 17, 2024
The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trialsKaoru Takase-Minegishi, Stefan Böhringer, Jackie L Nam, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Rheumatology and Therapy|July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.
The Lancet. Rheumatology|January 30, 2024
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 studyLaura C Coates, William Tillett, Maria-Antonietta D'Agostino, et al.
RMD Open|December 19, 2023
Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trialMichaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Frontiers in Medicine|November 7, 2025
Effect of thyme-ivy syrup on antiviral immune response in patients with mild COVID-19: a prospective, open-label, randomized pilot studyStephanie Dauth, Stephan M G Schäfer, Maximilian Klippstein, et al.
Rheumatology and Therapy|March 18, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical TrialLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
Annals of the Rheumatic Diseases|March 30, 2007
Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritisFrank Behrens, Andrea Himsel, Stefan Rehart, et al.
Arthritis Care & Research|January 8, 2020
Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease ManifestationsPhilip J Mease, Dafna D Gladman, Alexis Ogdie, et al.
Annals of the Rheumatic Diseases|May 15, 2020
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trialClaudia Kedor, Joachim Listing, Jan Zernicke, et al.
Scientific Reports|January 14, 2025
Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infectionsSamuel Rischke, Robert Gurke, Ann-Sophie Zielbauer, et al.
Rheumatology (Oxford, England)|February 17, 2024
The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trialsKaoru Takase-Minegishi, Stefan Böhringer, Jackie L Nam, et al.
Pageof 12